akampion News

Please click here to subscribe to regular news updates from the akampioneer.com
Tuesday, July 28, 2015

Company News: PNAS Paper Details Efficacy of a Potent, Fully Human Antibody for the Treatment of MERS

- First human-derived antibody which is suitable for prophylaxis, post-exposure prophylaxis, and treatment of MERS

- Therapeutic compound under development by Humabs BioMed on a non-profit basis

Humabs BioMed SA, a leading Swiss antibody therapeutics company, today announced that Proceedings of the National Academy of Sciences (PNAS) has published a paper describing the isolation and characterization of a potent antibody from memory B-cells of a patient recovering from an infection with coronavirus (CoV) and the resulting Middle East Respiratory Syndrome (MERS). The antibody, which was isolated from the infected individual two years ago, is active against all three clinically relevant MERS-CoV strains and against a site that is conserved in all MERS strains, including the strain responsible for the latest outbreak in South Korea. Humabs has developed a production cell line allowing  – depending on regulatory clearance – the antibody either to be made available on the basis of a compassionate use program or to enter Phase I trials within a few months.

Tuesday, July 28, 2015

Company News: Towards a Best Practice Approach in Cancer Immunotherapy: Cancer Vaccines Gain Momentum

 

- Review in The Journal of Clinical Investigation points the way forward for therapeutic cancer vaccines

ISA Pharmaceuticals B.V., a clinical-stage immunotherapy company focusing on rationally designed immunotherapeutics against cancer and persistent viral infections, today announced the publication of a comprehensive scientific review[1] of therapeutic cancer vaccines, outlining the best available strategies for successfully eradicating tumors with immunotherapy. The article, which was published in The Journal of Clinical Investigation, was authored by a group of scientists from Leiden University Medical Center (LUMC); lead author is Cornelis Melief, professor at LUMC and CSO of ISA Pharmaceuticals. The researchers point out that considerable progress has been made with therapeutic cancer vaccines, resulting in prolonged patient survival, but also conclude that most strategies have not resulted in objective, durable tumor regressions.